ClinicalTrials.gg
TerminatedNCT03881488Updated Oct 9, 2026Results posted

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

A Phase 1 interventional study of CTX-471 and Pembrolizumab (KEYTRUDA®) in Locally Advanced Solid Tumor, Metastatic Cancer and Non-small Cell Lung Cancer, sponsored by Compass Therapeutics. Terminated at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Compass Therapeutics · Phase 1, Interventional, and Treatment

Why this study was terminated
The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm was terminated. The monotherapy arm of the study was fully enrolled and completed.
Updated Oct 9, 2026Now TerminatedResults posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 2,056 studies in Neoplasm Metastasis with a site in United States — 346 open to participants now, 543 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Enrollment
521st of 1,865
100 · median 43
Started
2019
with 89 others
Phase 1
710 of 2,056
128 open now
Registered
1,320th of 2,056
by date

Among the 2,056 studies in Neoplasm Metastasis with a site in United States, this one is the 521st largest by enrollment of the 1,865 interventional ones that give a count, is one of 90 that started in 2019, is one of 710 in phase 1, and was the 1,320th registered.

Neoplasm Metastasis

4,051 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

346 of the 2,056 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 693 Neoplasm Metastasis studies recruiting now, 541 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,056 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving an approved PD-1 or PD-L1 inhibitor. The study will be conducted in 2 treatment arms (Monotherapy Arm 1 and Combination Arm 2). Each arm will have two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In each arm (monotherapy and combination therapy), data from Part 1 (dose escalation) and Part 2 (dose expansion) were combined by dose level for reporting.

03

Conditions studied

  • Locally Advanced Solid Tumor
  • Metastatic Cancer
  • Non-small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Mesothelioma
  • Melanoma
  • Head and Neck Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older
  2. confirmed diagnosis:

    1. Monotherapy Arm 1 ( Part 1 and 2): or locally advanced
    2. Combination Arm 2 Par 1 Dose Escalation: metastatic or locally advanced non-small cell lung, small cell lung cancer, mesothelioma, melanoma, or head and neck cancer
    3. Combination Arm 2 Part 2 Dose Expansion: metastatic or locally advanced non-small cell lung, small cell lung cancer, or melanoma
  3. per 1.1
  4. Disease progression after at least 12 weeks and at least 2 doses of a commercially available or PD-L1 inhibitor per approved prescriber's information, whether monotherapy or in combination therapy, with no other intervening systemic anticancer therapy prior to enrollment
  5. (ECOG) performance status 0-1
  6. > 12 weeks
  7. Adequate bone marrow function defined by of ≥ 1.5×10\^9/L, count of ≥100.0×10\^9/L, and of ≥ 9.0 g/dL (with or without transfusion)

    a. For Combination Arm 2: these criteria must be met without packed red blood cell (pRBC) transfusion within the prior 2 weeks. Patients can be on a stable dose of erythropoietin (≥ approximately 3 months)

  8. Adequate hepatic function defined as serum total \< 1.5 , /ALT ≤ 2.5 × ULN (or ≤ 5 × ULN in patients with liver metastases)
  9. Adequate renal function defined as > 30 mL/min as determined by the Cockcroft-Gault equation
  10. Female patients must be surgically sterile (or have a monogamous partner who is surgically sterile) or be least 2 years or commits to use 2 acceptable forms of (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study and for 4 months following the last dose of study treatment. Male patients must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 4 months following the last dose of study treatment
  11. Female patients who are women of (WCBP) must have a negative serum pregnancy test at Screening within 7 days of dosing with CTX-471 for Monotherapy Arm 1, and within 72 hours of dosing with CTX-471 and pembrolizumab for Combination Arm 2
  12. For Monotherapy Arm 1 Only: Last dose of previous PD-1 or PD-L1 therapy ≥ 28 days, other anticancer therapy > 21 days (or 2 half-lives for proteins, whichever is longer), radiotherapy > 21 days (concurrent localized palliative radiotherapy is allowed during CTX-471 treatment), or surgical intervention >21 days prior to the first dose of CTX-471
  13. Resolution of all prior anti-cancer therapy toxicities ≤ Grade 1. Note: Patients must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Patients with ≤Grade 2 neuropathy may be eligible. Patients with endocrine-related AEs Grade ≤2 requiring treatment or hormone replacement may be eligible.
  14. For Monotherapy Arm 1 Only: Willingness to provide pre- and post-treatment fresh tumor
  15. Capable of understanding and complying with protocol requirements
  16. Signed and dated institutional review board/independent ethics committee-approved form before any protocol-directed screening procedures are performed

Exclusion criteria

Exclusion Criteria:

  1. Developed adverse reaction to or PD-L1 therapy, including immune related adverse reactions, which led to discontinuation of treatment
  2. Prior treatment with other immune-oncology therapies
  3. Systemic therapy with agents within 7 days before the start of CTX-471 treatment. Topical, intranasal, intraocular, or inhaled and physiologic replacement for patients with adrenal insufficiency are allowed
  4. Patient is a pregnant or lactating WCBP
  5. Prior solid organ transplantation
  6. Active virus (HBV), virus (HCV), or infection (HIV) or a positive serological test at Screening within 28 days of dosing with CTX 471

    1. Participants who are HBsAg (hepatitis B surface antigen) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization Note: Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention
    2. Participants with history of HCV infection are eligible if HCV viral load is undetectable at screening Note: Participants must have completed curative anti-viral therapy at least 4 weeks prior to randomization
    3. HIV infected participants must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease defined as:

      • Participants on ART must have a >350 cells/mm3 at time of screening
      • Participants on ART must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 copies/mL or the lower limit of qualification (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks prior to screening
      • Participants on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks prior to study entry (Day 1)
  7. Active disease or medical conditions requiring chronic steroid (ie, > 10 mg/day prednisone or equivalent) or immunosuppressive therapy. Patients with a prior history of autoimmune disease may be eligible following discussion with the Medical Monitor
  8. For Monotherapy Arm 1 Only: History of central nervous system
  9. History of seizure disorders
  10. Congestive heart failure (> Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or clinically significant cardiac arrhythmias
  11. Other systemic conditions or organ abnormalities that in the opinion of the Investigator may interfere with the conduct and/or interpretation of the current study
  12. For Combination Arm 2 Only: Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks (could consider shorter interval for kinase inhibitors or other short half-life drugs) prior to treatment. Note: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Participants with ≤ Grade 2 neuropathy may be eligible. Participants with endocrine-related AEs Grade ≤ 2 requiring treatment or hormone replacement may be eligible Note: If the participant had major surgery, the participant must have recovered adequately from the procedure and/or any complications from the surgery prior to starting study intervention
  13. For Combination Arm 2 Only: Has received prior radiotherapy within 2 weeks of start of study treatment or have had a history of radiation pneumonitis Note: Participants must have recovered from all radiation-related toxicities and not require corticosteroids. A 1-week is permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-CNS disease
  14. For Combination Arm 2 Only: Has had an allogeneic tissue transplant
  15. For Combination Arm 2 Only: Has received a live or within 30 days prior to the first dose of study intervention. Note: Administration of killed vaccines are allowed
  16. For Combination Arm 2 Only: Has a known additional that is progressing or has required active treatment within the past 3 years Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of bladder, that have undergone potentially curative therapy are not excluded
  17. For Combination Arm 2 Only: Has known active and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment
  18. For Combination Arm 2 Only: Has severe (≥ Grade 3) to pembrolizumab and/or any of its
  19. For Combination Arm 2 Only: Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease
  20. For Combination Arm 2 Only: Has an active infection requiring systemic therapy
  21. For Combination Arm 2 Only: Has a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator
  22. For Combination Arm 2 Only: Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
  23. For Combination Arm 2 Only: Has received radiation therapy to the lung that is > 30Gy within 6 months of the first dose of trial treatment
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Arm 1 Part 1 Dose Escalation

    Escalating doses of CTX-471 depending on cohort at enrollment

    Drug: CTX-471

  • Experimental
    Arm 1 Part 2 Dose Expansion

    Two dose groups of CTX-471 (0.3 mg/kg and 0.6 mg/kg)

    Drug: CTX-471

  • Experimental
    Arm 2 Part 1 Dose Escalation

    Escalating doses of CTX-471 in combination with pembrolizumab (KEYTRUDA® ) depending on cohort at enrollment

    Drug: CTX-471 · Drug: Pembrolizumab (KEYTRUDA®)

  • Experimental
    Arm 2 Part 2 Dose Expansion

    Two cohorts of CTX-471 (0.3 mg/kg and 0.6 mg/kg) in combination with pembrolizumab (KEYTRUDA® ) (400 mg) in three tumor type subgroups. Cohort 1 - Group 1A - NSCLC , Group 1B -SCLC and Group 1C - Melanoma. Cohort 2 Group 2A - NSCLC, Group 2B - SCLC and Group 2C -Melanoma.

    Drug: CTX-471 · Drug: Pembrolizumab (KEYTRUDA®)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities (DLTs), Treatment-emergent Adverse Events (TEAEs), and/or Changes in Clinical Laboratory Abnormalities

    Hematological and nonhematological DLTs were defined in the protocol. TEAE is an occurrence of an adverse event that started or worsened in severity on or after the first dose of CTX-471. Change in clinical laboratory abnormalities is defined as a TEAE related to laboratory results.

    Time frame: From first CTX-471 dose to 4 weeks after first dose for DLTs in monotherapy arms, to 6 weeks after first dose for DLTs in combination arms, to 60 days after last dose for TEAEs and clinical laboratory abnormalities in both monotherapy and combination arms

Secondary outcomes

  1. Maximum Serum Concentration (Cmax) of CTX-471

    Calculated from plasma concentrations measured from samples collected at times shown below

    Time frame: Monotherapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose; before Week 9 dose; 1, 6, 24 hours and 2 weeks after Week 9 dose. Combination therapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose.

  2. Area Under the Serum Concentrations of CTX-471 Versus Time Curve (AUC)

    AUC(0-24) = AUC from time 0 to 24 hours (1 day); AUC(0-336) = AUC from time 0 to 336 hours (14 days). Calculated from plasma concentrations measured from samples collected at the time points below.

    Time frame: Monotherapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose; before Week 9 dose; 1, 6, 24 hours after Week 9 dose. Combination therapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose.

  3. Half-life (t1/2) of Serum Concentration of CTX-471

    Time frame: Calculated from plasma concentrations measured from samples collected before the first dose of CTX-471; 1, 6, and 24 hours after the first dose of CTX-471; and before the second dose of CTX-471 (Weeks 1 to 3)

  4. Development of Anti-drug Antibodies

    Frequency of patients with a negative test result for antibody to CTX-471 prior to treatment who had a positive test for antibody to CTX-471 after treatment. For monotherapy arms, end of treatment was an average 18 weeks, and 60 days after end of treatment was an average 27 weeks. For combination arms, end of treatment was an average 15 weeks, and 60 days after end of treatment was an average 24 weeks.

    Time frame: Monotherapy arms: Weeks 3, 5, 9, 13, 17, 21, 25, 29, 33, and 37 and end of treatment and 60 days after end of treatment; Combination therapy arms: Weeks 5, 9, 13, 19, 25, 31, and 37 and end of treatment and 60 days after end of treatment

  5. Overall Response Rate

    Percentage of patients whose best overall response to treatment was complete response or partial response (as assessed by Response Evaluation Criteria in Solid Tumours guideline version 1.1)

    Time frame: From the first dose of CTX-471 to treatment discontinuation (average of 18 weeks for monotherapy groups and and average of 15 weeks for combination groups)

  6. Duration of Response

    Time period from date of CT or MRI that first confirmed complete or partial response to date of CT or MRI that first confirmed progression of disease (as assessed by Response Evaluation Criteria in Solid Tumours guideline version 1.1)

    Time frame: From first date of complete or partial response to first date of disease progression or death

  7. Progression-free Survival

    Time from the first dose of CTX-471 to disease progression (as assessed by Response Evaluation Criteria in Solid Tumours guideline version 1.1) or death

    Time frame: From the first dose of CTX-471 to progression of disease or death

  8. Overall Survival

    Time from the first dose of CTX-471 to death

    Time frame: From the first dose of CTX-471 to death

07

Results

Posted Oct 9, 2026

Participant flow

Participant flow — Overall Study
MilestoneCTX-471 Monotherapy 0.1 mg/kgCTX-471 Monotherapy 0.3 mg/kgCTX-471 Monotherapy 0.6 mg/kgCTX-471 Monotherapy 1.2 mg/kgCTX-471 Combination 0.1 mg/kgCTX-471 Combination 0.3 mg/kgCTX-471 Combination 0.6 mg/kg
Started333367399
Completed0532000
Not completed328335399
Withdrew: Death322305255
Withdrew: Lost to follow-up0210000
Withdrew: Physician decision0010000
Withdrew: Withdrawal by subject0300022
Withdrew: Study termination by sponsor0100122
Withdrew: Clinical deterioration0010000

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities (DLTs), Treatment-emergent Adverse Events (TEAEs), and/or Changes in Clinical Laboratory Abnormalities

Hematological and nonhematological DLTs were defined in the protocol. TEAE is an occurrence of an adverse event that started or worsened in severity on or after the first dose of CTX-471. Change in clinical laboratory abnormalities is defined as a TEAE related to laboratory results.

Time frame:
From first CTX-471 dose to 4 weeks after first dose for DLTs in monotherapy arms, to 6 weeks after first dose for DLTs in combination arms, to 60 days after last dose for TEAEs and clinical laboratory abnormalities in both monotherapy and combination arms
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLTs), Treatment-emergent Adverse Events (TEAEs), and/or Changes in Clinical Laboratory Abnormalities
ParticipantsCTX-471 Monotherapy 0.1 mg/kgCTX-471 Monotherapy 0.3 mg/kgCTX-471 Monotherapy 0.6 mg/kgCTX-471 Monotherapy 1.2 mg/kgCTX-471 Combination 0.1 mg/kgCTX-471 Combination 0.3 mg/kgCTX-471 Combination 0.6 mg/kg
Dose-limiting toxicity0002000
Treatment-emergent adverse event133367389
Blood creatinine increased0741110
Alanine aminotransferase increased0332000
Aspartate aminotransferase increased0251000
Blood alkaline phosphatase increased0430000
Lipase increased0230101
Amylase increased0130100
Platelet count decreased1111000
International normalised ratio increased0210000
Lymphocyte count decreased0200010
Transaminases increased0001000
Activated partial thromboplastin time prolonged0100000
Bilirubin conjugated increased0100000
Blood bilirubin increased0100001
Blood lactate dehydrogenase increased0010000
Blood lactic acid increased0010000
Blood phosphorus decreased0100000
Blood thyroid stimulating hormone decreased0000001
Carbon dioxide decreased0100001
Troponin increased0010000
White blood cell count decreased0010001
White blood cell count increased0010000
Hyponatraemia0590001
Hyperkalaemia0221000
Hypomagnesaemia0130100
Hypophosphataemia0301000
Hypokalaemia0210102
Hyperphosphataemia0200000
Hypoalbuminaemia0110011
Hypocalcaemia0110100
Hypercalcaemia0101000
Hyperglycaemia0100000
Hypermagnesaemia0100000
Hypernatraemia0100100
Hypoglycaemia0100000
Anaemia19123121
Neutropenia0110000
Thrombocytopenia0100000
SecondaryMaximum Serum Concentration (Cmax) of CTX-471

Calculated from plasma concentrations measured from samples collected at times shown below

Time frame:
Monotherapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose; before Week 9 dose; 1, 6, 24 hours and 2 weeks after Week 9 dose. Combination therapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose.
Reported as:
Geometric mean · ng/mL
Maximum Serum Concentration (Cmax) of CTX-471
ng/mLCTX-471 Monotherapy 0.1 mg/kgCTX-471 Monotherapy 0.3 mg/kgCTX-471 Monotherapy 0.6 mg/kgCTX-471 Monotherapy 1.2 mg/kgCTX-471 Combination 0.1 mg/kgCTX-471 Combination 0.3 mg/kgCTX-471 Combination 0.6 mg/kg
Week 1 dose1564.5 ± 35.26308.4 ± 52.911249.9 ± 33.825403.4 ± 30.2NA ± NA7612.2 ± 4.27152.2 ± 286.3
Week 9 dose (steady state)2950.0 ± NA9880.4 ± 34.910998.7 ± 17.625731.7 ± 38.1———
SecondaryArea Under the Serum Concentrations of CTX-471 Versus Time Curve (AUC)

AUC(0-24) = AUC from time 0 to 24 hours (1 day); AUC(0-336) = AUC from time 0 to 336 hours (14 days). Calculated from plasma concentrations measured from samples collected at the time points below.

Time frame:
Monotherapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose; before Week 9 dose; 1, 6, 24 hours after Week 9 dose. Combination therapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose.
Reported as:
Geometric mean · h∙ng/mL
Area Under the Serum Concentrations of CTX-471 Versus Time Curve (AUC)
h∙ng/mLCTX-471 Monotherapy 0.1 mg/kgCTX-471 Monotherapy 0.3 mg/kgCTX-471 Monotherapy 0.6 mg/kgCTX-471 Monotherapy 1.2 mg/kgCTX-471 Combination 0.1 mg/kgCTX-471 Combination 0.3 mg/kgCTX-471 Combination 0.6 mg/kg
Week 1 AUC(0-24)33849.4 ± 38.4123698.8 ± 50.5208795.6 ± 38.7498570.5 ± 32.5NA ± NA161090.8 ± 6.8149520.7 ± 344.0
Week 1 AUC(0-336)223886.8 ± 41.7818109.9 ± 45.71579811.4 ± 27.53500751.4 ± 37.5NA ± NA1123811.4 ± 24.31034157.2 ± 357.5
Week 9 (steady state) AUC(0-24)66000.0 ± NA184610.2 ± 21.9224875.8 ± 16.7466764.0 ± 55.4———
SecondaryHalf-life (t1/2) of Serum Concentration of CTX-471
Time frame:
Calculated from plasma concentrations measured from samples collected before the first dose of CTX-471; 1, 6, and 24 hours after the first dose of CTX-471; and before the second dose of CTX-471 (Weeks 1 to 3)
Reported as:
Geometric mean · hours
Half-life (t1/2) of Serum Concentration of CTX-471
hoursCTX-471 Monotherapy 0.1 mg/kgCTX-471 Monotherapy 0.3 mg/kgCTX-471 Monotherapy 0.6 mg/kgCTX-471 Monotherapy 1.2 mg/kgCTX-471 Combination 0.1 mg/kgCTX-471 Combination 0.3 mg/kgCTX-471 Combination 0.6 mg/kg
Half-life (t1/2) of Serum Concentration of CTX-471147.9 ± 9.1163.6 ± 27.8159.2 ± 24.4156.6 ± 19.9126.9 ± 35.6145.3 ± 30.5167.8 ± 16.3
SecondaryDevelopment of Anti-drug Antibodies

Frequency of patients with a negative test result for antibody to CTX-471 prior to treatment who had a positive test for antibody to CTX-471 after treatment. For monotherapy arms, end of treatment was an average 18 weeks, and 60 days after end of treatment was an average 27 weeks. For combination arms, end of treatment was an average 15 weeks, and 60 days after end of treatment was an average 24 weeks.

Time frame:
Monotherapy arms: Weeks 3, 5, 9, 13, 17, 21, 25, 29, 33, and 37 and end of treatment and 60 days after end of treatment; Combination therapy arms: Weeks 5, 9, 13, 19, 25, 31, and 37 and end of treatment and 60 days after end of treatment
Reported as:
Count of participants · Participants
Development of Anti-drug Antibodies
ParticipantsCTX-471 Monotherapy 0.1 mg/kgCTX-471 Monotherapy 0.3 mg/kgCTX-471 Monotherapy 0.6 mg/kgCTX-471 Monotherapy 1.2 mg/kgCTX-471 Combination 0.1 mg/kgCTX-471 Combination 0.3 mg/kgCTX-471 Combination 0.6 mg/kg
Week 30011———
Week 50000000
Week 90000010
Week 132000010
Week 170110———
Week 19————010
Week 210210———
Week 250200010
Week 290100———
Week 31————010
Week 330100———
Week 370100010
End of Treatment0120121
60 days after end of treatment0100001
SecondaryOverall Response Rate

Percentage of patients whose best overall response to treatment was complete response or partial response (as assessed by Response Evaluation Criteria in Solid Tumours guideline version 1.1)

Time frame:
From the first dose of CTX-471 to treatment discontinuation (average of 18 weeks for monotherapy groups and and average of 15 weeks for combination groups)
Reported as:
Count of participants · Participants
Overall Response Rate
ParticipantsCTX-471 Monotherapy 0.1 mg/kgCTX-471 Monotherapy 0.3 mg/kgCTX-471 Monotherapy 0.6 mg/kgCTX-471 Monotherapy 1.2 mg/kgCTX-471 Combination 0.1 mg/kgCTX-471 Combination 0.3 mg/kgCTX-471 Combination 0.6 mg/kg
Overall Response Rate0410000
SecondaryDuration of Response

Time period from date of CT or MRI that first confirmed complete or partial response to date of CT or MRI that first confirmed progression of disease (as assessed by Response Evaluation Criteria in Solid Tumours guideline version 1.1)

Time frame:
From first date of complete or partial response to first date of disease progression or death
Reported as:
Median · months
Duration of Response
monthsCTX-471 Monotherapy 0.1 mg/kgCTX-471 Monotherapy 0.3 mg/kgCTX-471 Monotherapy 0.6 mg/kgCTX-471 Monotherapy 1.2 mg/kgCTX-471 Combination 0.1 mg/kgCTX-471 Combination 0.3 mg/kgCTX-471 Combination 0.6 mg/kg
Duration of Response—24.43 (1.88 to 46.97)3.55 (3.55 to 3.55)————
SecondaryProgression-free Survival

Time from the first dose of CTX-471 to disease progression (as assessed by Response Evaluation Criteria in Solid Tumours guideline version 1.1) or death

Time frame:
From the first dose of CTX-471 to progression of disease or death
Reported as:
Median · months
Progression-free Survival
monthsCTX-471 Monotherapy 0.1 mg/kgCTX-471 Monotherapy 0.3 mg/kgCTX-471 Monotherapy 0.6 mg/kgCTX-471 Monotherapy 1.2 mg/kgCTX-471 Combination 0.1 mg/kgCTX-471 Combination 0.3 mg/kgCTX-471 Combination 0.6 mg/kg
Progression-free Survival3.55 (1.64 to 5.49)3.55 (0.95 to 42.07)3.52 (1.51 to 14.77)3.05 (1.74 to 4.21)1.84 (1.58 to 20.53)2.89 (1.64 to 14.77)2.36 (1.18 to 3.68)
SecondaryOverall Survival

Time from the first dose of CTX-471 to death

Time frame:
From the first dose of CTX-471 to death
Reported as:
Median · months
Overall Survival
monthsCTX-471 Monotherapy 0.1 mg/kgCTX-471 Monotherapy 0.3 mg/kgCTX-471 Monotherapy 0.6 mg/kgCTX-471 Monotherapy 1.2 mg/kgCTX-471 Combination 0.1 mg/kgCTX-471 Combination 0.3 mg/kgCTX-471 Combination 0.6 mg/kg
Overall Survival14.70 (9.57 to 14.90)14.64 (1.38 to 49.87)9.41 (0.72 to 28.32)11.05 (2.43 to 22.73)4.05 (3.55 to 26.78)8.65 (0.26 to 19.14)6.78 (2.07 to 21.48)

Adverse events

Collected over From the signing of the informed consent form through 60 days after the last dose of CTX-471 (average of 27 weeks) for the monotherapy arms, from the signing of the informed consent form through 90 days after the last dose of pembrolizumab (average of 28 weeks) for the combination arms. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CTX-471 Monotherapy 0.1 mg/kg3/3 (100%)1/3 (33.3%)2/3 (66.7%)
CTX-471 Monotherapy 0.3 mg/kg22/33 (66.7%)11/33 (33.3%)33/33 (100%)
CTX-471 Monotherapy 0.6 mg/kg30/36 (83.3%)17/36 (47.2%)36/36 (100%)
CTX-471 Monotherapy 1.2 mg/kg5/7 (71.4%)3/7 (42.9%)7/7 (100%)
CTX-471 Combination 0.1 mg/kg2/3 (66.7%)2/3 (66.7%)3/3 (100%)
CTX-471 Combination 0.3 mg/kg5/9 (55.6%)2/9 (22.2%)8/9 (88.9%)
CTX-471 Combination 0.6 mg/kg5/9 (55.6%)4/9 (44.4%)9/9 (100%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
EventCTX-471 Monotherapy 0.1 mg/kgCTX-471 Monotherapy 0.3 mg/kgCTX-471 Monotherapy 0.6 mg/kgCTX-471 Monotherapy 1.2 mg/kgCTX-471 Combination 0.1 mg/kgCTX-471 Combination 0.3 mg/kgCTX-471 Combination 0.6 mg/kg
HypoxiaRespiratory, thoracic and mediastinal disorders1/31/331/360/70/30/90/9
Urinary tract infectionInfections and infestations0/31/330/360/71/30/90/9
Bile duct obstructionHepatobiliary disorders0/30/330/360/71/30/90/9
Acute kidney injuryRenal and urinary disorders0/30/330/360/71/30/90/9
Tubulointerstitial nephritisRenal and urinary disorders0/30/330/360/71/30/90/9
HeadacheNervous system disorders0/30/330/361/70/30/90/9
Pericardial effusionCardiac disorders0/30/330/361/70/30/90/9
AnaemiaBlood and lymphatic system disorders0/30/330/361/70/30/90/9
Platelet count decreasedInvestigations0/30/331/361/70/30/90/9
Pathological fractureMusculoskeletal and connective tissue disorders0/30/330/361/70/30/90/9
Most frequent other events
Showing 10 of 221
Most frequent other events
EventCTX-471 Monotherapy 0.1 mg/kgCTX-471 Monotherapy 0.3 mg/kgCTX-471 Monotherapy 0.6 mg/kgCTX-471 Monotherapy 1.2 mg/kgCTX-471 Combination 0.1 mg/kgCTX-471 Combination 0.3 mg/kgCTX-471 Combination 0.6 mg/kg
FatigueGeneral disorders0/313/3312/362/73/36/94/9
PyrexiaGeneral disorders1/34/335/362/72/32/90/9
PainGeneral disorders0/32/332/360/72/30/90/9
Decreased appetiteMetabolism and nutrition disorders1/36/336/360/72/35/93/9
NauseaGastrointestinal disorders1/39/3310/362/72/32/91/9
VomitingGastrointestinal disorders1/39/339/360/72/31/91/9
DyspnoeaRespiratory, thoracic and mediastinal disorders0/35/335/361/72/32/92/9
Pleural effusionRespiratory, thoracic and mediastinal disorders0/32/332/360/72/32/91/9
ArthralgiaMusculoskeletal and connective tissue disorders1/37/335/361/72/31/91/9
HypertensionVascular disorders0/33/334/360/72/33/90/9

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CTX-471 Monotherapy 0.1 mg/kgCTX-471 Monotherapy 0.3 mg/kgCTX-471 Monotherapy 0.6 mg/kgCTX-471 Monotherapy 1.2 mg/kgCTX-471 Combination 0.1 mg/kgCTX-471 Combination 0.3 mg/kgCTX-471 Combination 0.6 mg/kgTotal
<=18 years00000000
Between 18 and 65 years11212416238
>=65 years22124323762
Sex: Female, Male
Sex: Female, Male(Participants)CTX-471 Monotherapy 0.1 mg/kgCTX-471 Monotherapy 0.3 mg/kgCTX-471 Monotherapy 0.6 mg/kgCTX-471 Monotherapy 1.2 mg/kgCTX-471 Combination 0.1 mg/kgCTX-471 Combination 0.3 mg/kgCTX-471 Combination 0.6 mg/kgTotal
Female11214125338
Male22122614662
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CTX-471 Monotherapy 0.1 mg/kgCTX-471 Monotherapy 0.3 mg/kgCTX-471 Monotherapy 0.6 mg/kgCTX-471 Monotherapy 1.2 mg/kgCTX-471 Combination 0.1 mg/kgCTX-471 Combination 0.3 mg/kgCTX-471 Combination 0.6 mg/kgTotal
Hispanic or Latino01210004
Not Hispanic or Latino33134639995
Unknown or Not Reported01000001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CTX-471 Monotherapy 0.1 mg/kgCTX-471 Monotherapy 0.3 mg/kgCTX-471 Monotherapy 0.6 mg/kgCTX-471 Monotherapy 1.2 mg/kgCTX-471 Combination 0.1 mg/kgCTX-471 Combination 0.3 mg/kgCTX-471 Combination 0.6 mg/kgTotal
American Indian or Alaska Native00000000
Asian01300004
Native Hawaiian or Other Pacific Islander00000000
Black or African American12320008
White23030539988
More than one race00000000
Unknown or Not Reported00000000
Region of Enrollment
Region of Enrollment(participants)CTX-471 Monotherapy 0.1 mg/kgCTX-471 Monotherapy 0.3 mg/kgCTX-471 Monotherapy 0.6 mg/kgCTX-471 Monotherapy 1.2 mg/kgCTX-471 Combination 0.1 mg/kgCTX-471 Combination 0.3 mg/kgCTX-471 Combination 0.6 mg/kgTotal
United States333367399100
08

Study locations

10 sites
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Hematology Oncology Associates Of The Treasure Coast
    Port Saint Lucie, Florida 34952, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Washington University School of Medicine, Siteman Cancer Center
    St Louis, Missouri 63110, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Mt Sinai
    New York, New York 10029, United States
  • Duke University School of Medicine
    Durham, North Carolina 27705, United States
  • Institute for Translational Oncology Research (ITOR)
    Greenville, South Carolina 29605, United States
  • Mary Crowley Cancer Research
    Dallas, Texas 75251, United States
09

References and documents

Publications

  • Singh R, Kim YH, Lee SJ, Eom HS, Choi BK. 4-1BB immunotherapy: advances and hurdles. Exp Mol Med. 2024 Feb;56(1):32-39. doi: 10.1038/s12276-023-01136-4. Epub 2024 Jan 4. PubMed 38172595 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in May 2025, 72 months.

Results were first posted in Oct 2026, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2019
First posted
Mar 19, 2019
StartActual
May 17, 2019
Primary completionActual
May 21, 2025
CompletionActual
May 21, 2025
Results first posted
Oct 9, 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Terminated The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm was terminated. The monotherapy arm of the study was fully enrolled and completed.
changed Oct 9, 2026
Results
Results posted
posted Oct 9, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of participants with dose limiting toxicitiesParticipants With Dose Limiting Toxicities (DLTs), treatmentTreatment-emergent adverse eventsAdverse Events (TEAEs), and/or changesChanges in clinical laboratory abnormalitiesClinical Laboratory AbnormalitiesTime frame: From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years) → From first CTX-471 dose to 4 weeks after first dose for DLTs in monotherapy arms, to 6 weeks after first dose for DLTs in combination arms, to 60 days after last dose for TEAEs and clinical laboratory abnormalities in both monotherapy and combination arms
Oct 9, 2026
Documents
Secondary outcomes
3 edited, 5 added, 5 removed
What changed in the outcomes
  • EditedMaximum serum concentrationSerum Concentration (Cmax) of CTX-471 as a monotherapy and CTX-471 in combination with pembrolizumabTime frame: From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years) → Monotherapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose; before Week 9 dose; 1, 6, 24 hours and 2 weeks after Week 9 dose. Combination therapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose.
  • EditedArea underUnder the serum concentrationsSerum Concentrations of CTX-471 versus time curveVersus Time Curve (AUC) for CTX-471 as a monotherapy and CTX-471 in combination with pembrolizumabTime frame: From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years) → Monotherapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose; before Week 9 dose; 1, 6, 24 hours after Week 9 dose. Combination therapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose.
  • EditedHalf-life (t1/2) of serum concentrationsSerum Concentration of CTX-471 as a monotherapy and CTX-471 in combination with pembrolizumabTime frame: From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years) → Calculated from plasma concentrations measured from samples collected before the first dose of CTX-471; 1, 6, and 24 hours after the first dose of CTX-471; and before the second dose of CTX-471 (Weeks 1 to 3)
  • AddedDevelopment of Anti-drug AntibodiesTime frame: Monotherapy arms: Weeks 3, 5, 9, 13, 17, 21, 25, 29, 33, and 37 and end of treatment and 60 days after end of treatment; Combination therapy arms: Weeks 5, 9, 13, 19, 25, 31, and 37 and end of treatment and 60 days after end of treatment
  • AddedOverall Response RateTime frame: From the first dose of CTX-471 to treatment discontinuation (average of 18 weeks for monotherapy groups and and average of 15 weeks for combination groups)
  • AddedDuration of ResponseTime frame: From first date of complete or partial response to first date of disease progression or death
  • AddedProgression-free SurvivalTime frame: From the first dose of CTX-471 to progression of disease or death
  • AddedOverall SurvivalTime frame: From the first dose of CTX-471 to death
  • RemovedDevelopment of anti-drug antibodies (ADAs) and/or neutralizing antibodies of CTX-471 as a monotherapy and CTX-471 in combination with pembrolizumabTime frame: From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years)
  • RemovedObjective Response Rate (ORR) (Percentage of Participants With Objective Response) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 of CTX-471 as a monotherapy and CTX-471 in combination with pembrolizumabTime frame: Baseline until confirmed disease progression (CR or PR) (up to 2 years)
  • RemovedDuration of Response (DOR) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 of CTX-471 as a monotherapy and CTX-471 in combination with pembrolizumabTime frame: From the date of first confirmed CR or PR until the first date of recurrent or progressive disease (up to 2 years)
  • RemovedProgression-Free Survival (PFS) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 of CTX-471 as a monotherapy and CTX-471 in combination with pembrolizumabTime frame: From first dose of CTX-471 (Week 1 Day 1) until disease progression or death, whichever occur first (up to 2 years)
  • RemovedOverall Survival (OS) of CTX-471 as a monotherapy and CTX-471 in combination with pembrolizumabTime frame: From first dose of CTX-471 (Week 1 Day 1) until death (up to 2 years)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Completed→Terminated
    Why stopped The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm was terminated. The monotherapy arm of the study was fully enrolled and completed.
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of participants with dose limiting toxicitiesParticipants With Dose Limiting Toxicities (DLTs), treatmentTreatment-emergent adverse eventsAdverse Events (TEAEs), and/or changesChanges in clinical laboratory abnormalitiesClinical Laboratory AbnormalitiesTime frame: From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years) → From first CTX-471 dose to 4 weeks after first dose for DLTs in monotherapy arms, to 6 weeks after first dose for DLTs in combination arms, to 60 days after last dose for TEAEs and clinical laboratory abnormalities in both monotherapy and combination arms
    Secondary outcomes 3 edited, 5 added, 5 removed
    What changed in the outcomes
    • EditedMaximum serum concentrationSerum Concentration (Cmax) of CTX-471 as a monotherapy and CTX-471 in combination with pembrolizumabTime frame: From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years) → Monotherapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose; before Week 9 dose; 1, 6, 24 hours and 2 weeks after Week 9 dose. Combination therapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose.
    • EditedArea underUnder the serum concentrationsSerum Concentrations of CTX-471 versus time curveVersus Time Curve (AUC) for CTX-471 as a monotherapy and CTX-471 in combination with pembrolizumabTime frame: From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years) → Monotherapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose; before Week 9 dose; 1, 6, 24 hours after Week 9 dose. Combination therapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose.
    • EditedHalf-life (t1/2) of serum concentrationsSerum Concentration of CTX-471 as a monotherapy and CTX-471 in combination with pembrolizumabTime frame: From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years) → Calculated from plasma concentrations measured from samples collected before the first dose of CTX-471; 1, 6, and 24 hours after the first dose of CTX-471; and before the second dose of CTX-471 (Weeks 1 to 3)
    • AddedDevelopment of Anti-drug AntibodiesTime frame: Monotherapy arms: Weeks 3, 5, 9, 13, 17, 21, 25, 29, 33, and 37 and end of treatment and 60 days after end of treatment; Combination therapy arms: Weeks 5, 9, 13, 19, 25, 31, and 37 and end of treatment and 60 days after end of treatment
    • AddedOverall Response RateTime frame: From the first dose of CTX-471 to treatment discontinuation (average of 18 weeks for monotherapy groups and and average of 15 weeks for combination groups)
    • AddedDuration of ResponseTime frame: From first date of complete or partial response to first date of disease progression or death
    • AddedProgression-free SurvivalTime frame: From the first dose of CTX-471 to progression of disease or death
    • AddedOverall SurvivalTime frame: From the first dose of CTX-471 to death
    • RemovedDevelopment of anti-drug antibodies (ADAs) and/or neutralizing antibodies of CTX-471 as a monotherapy and CTX-471 in combination with pembrolizumabTime frame: From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years)
    • RemovedObjective Response Rate (ORR) (Percentage of Participants With Objective Response) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 of CTX-471 as a monotherapy and CTX-471 in combination with pembrolizumabTime frame: Baseline until confirmed disease progression (CR or PR) (up to 2 years)
    • RemovedDuration of Response (DOR) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 of CTX-471 as a monotherapy and CTX-471 in combination with pembrolizumabTime frame: From the date of first confirmed CR or PR until the first date of recurrent or progressive disease (up to 2 years)
    • RemovedProgression-Free Survival (PFS) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 of CTX-471 as a monotherapy and CTX-471 in combination with pembrolizumabTime frame: From first dose of CTX-471 (Week 1 Day 1) until disease progression or death, whichever occur first (up to 2 years)
    • RemovedOverall Survival (OS) of CTX-471 as a monotherapy and CTX-471 in combination with pembrolizumabTime frame: From first dose of CTX-471 (Week 1 Day 1) until death (up to 2 years)
    + 3 other changes: index terms, description and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03881488
Lead sponsor
Compass Therapeutics
Collaborators
IQVIA Pty Ltd, Merck, Sharp & Dohme, LLC, Rahway, NJ USA
Responsible party
Sponsor
First posted
Mar 19, 2019
Start date
May 17, 2019
Primary completion
May 21, 2025
Completion
May 21, 2025
Results posted
Oct 9, 2026
Last update
Oct 9, 2026

Study contacts

Thomas Scheutz, MD, PhD
study director · Compass Therapeutics

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion